Mustang Bio (MBIO) Non Operating Income (2016 - 2026)
Mustang Bio (MBIO) posted quarterly Non Operating Income of $103000.0 for Q1 2026, up 3.0% year-over-year from $100000.0 in Q1 2025, and down 21.97% quarter-over-quarter from $132000.0 in Q4 2025.
Mustang Bio (MBIO) Non Operating Income (2016 - 2026) Analysis & Trends
Mustang Bio (MBIO) has reported Non Operating Income for 11 consecutive years, with $103000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income rose 3.0% year-over-year to $103000.0; the TTM figure through Mar 2026 stood at $514000.0 (down 7.05% YoY), while the FY2025 annual figure was $511000.0, up 3.65% from the prior year.
- Non Operating Income slipped to $103000.0 in Q1 2026 per MBIO's latest filing, from $132000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $341000.0 in Q2 2024 and bottomed at -$2.3 million in Q2 2023.
- Historically, Non Operating Income has averaged -$153000.0 across 5 years, with a median of $65000.0 in 2024.
- Annual changes were most pronounced in 2022 — Non Operating Income tumbled 1159.26% — and 2023, when it surged 267.11%.
- Mustang Bio's Non Operating Income stood at -$202000.0 in 2022, then jumped by 161.88% to $125000.0 in 2023, then sank by 48.0% to $65000.0 in 2024, then jumped by 103.08% to $132000.0 in 2025, then retreated by 21.97% to $103000.0 in 2026.
- Business Quant data shows MBIO's Non Operating Income at $103000.0 in Q1 2026, $132000.0 in Q4 2025, and $156000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Mustang Bio | 3.90 Mn | 3.90 Mn | - | 98,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 98,000.00 |
| Mar 31, 2026 | 103,000.00 |
| Dec 31, 2025 | 132,000.00 |
| Sep 30, 2025 | 156,000.00 |
| Jun 30, 2025 | 123,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 65,000.00 |
| Sep 30, 2024 | 47,000.00 |
| Jun 30, 2024 | 341,000.00 |
| Mar 31, 2024 | 40,000.00 |
| Dec 31, 2023 | 125,000.00 |
| Sep 30, 2023 | 249,000.00 |
| Jun 30, 2023 | -2.34 Mn |
| Mar 31, 2023 | -372,000.00 |
| Dec 31, 2022 | -202,000.00 |
| Sep 30, 2022 | -149,000.00 |
| Jun 30, 2022 | -858,000.00 |
| Mar 31, 2022 | -157,000.00 |
| Dec 31, 2021 | 70,000.00 |
| Sep 30, 2021 | 72,000.00 |